In Vivo CD19 CAR-T Cell Engineering with Endless RNA (eRNA) & Pan-T Cell-Targeted Lipid Nanoparticles Drives Deep B-Cell Depletion & Immune Reset with Superior Dose Potency
11:00 am - Wednesday 2nd December 2026
- Discuss how eRNA achieves up to 240-fold greater CAR expression than mRNA in primary resting human T-cells, translating directly into approximately 2 logs greater depth of B-cell depletion in lymphoid tissues in vivo at matched dose levels
- Explore how Sail’s eRNA-TNP platform achieves greater than 99% B-cell depletion across all lymphoid compartments in two distinct humanized mouse models including lymph nodes where existing biologics fail and drives immune reset of the B-cell compartment, recapitulating the pharmacological signature of curative ex vivo CAR-T therapy
- Evaluate how in non-human primates, we establish for the first time that lymph node depletion is uniquely sensitive to drug potency relative to other lymphoid tissues, defining a potency threshold with direct implications for clinical candidate selection across the in vivo CAR-T field
